METHODS FOR PREDICTING TREATMENT RESPONSE BASED ON THE EXPRESSION PROFILES OF BIOMARKER GENES IN NOTCH MEDIATED CANCERS

• US 20110166028A1
• Filed: 08/22/2008
• Published: 07/07/2011
• Est. Priority Date: 08/28/2007
• Status: Abandoned Application

• Current Assignee: Dana-Farber Cancer Institute, Merck Sharp & Dohme Limited (Merck & Co., Inc.)
• Original Assignee: Merck Sharp & Dohme Limited (Merck & Co., Inc.)
• Inventors: Bergstrom, Donald, Liberator, Cole, Winter, Christopher, Rao, Sudhir, Zhang, Theresa, Strack, Peter, Hardwick, James, O'Neil, Jennifer, Look, A. Thomas, Dai, Xudong
• Application Number:
  US12/674,981
• Publication Number:
  US 20110166028A1
• Time in Patent Office: Days
• US Class Current: 506/7
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The invention relates to the identification and use of gene expression profiles with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. The same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. The methods may further comprise selecting a treatment based on the classifying step.

Claims

1-73. -73. (canceled)

74. A method for predicting the response of a patient diagnosed with a Notch mediated T-ALL to treatment with a Notch inhibitor comprising quantifying the gene expression level of a biomarker gene set designated Notch-10 comprising HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA and SHQ1 in a biological sample comprising cancer cells obtained from said subject to obtain a mean average expression level, wherein mean average expression level above or below a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

75. The method according to claim 74, an increase in the average gene expression level relative to a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

76. The method according to claim 74, wherein the predictive biomarker gene set comprises HES5, and wherein the average expression level of said gene set above or below a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

77. The method according to claim 74, wherein the predictive biomarker gene set comprises DTX1, and wherein the average expression level of said gene set above or below a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

78. The method according to claim 74, wherein the predictive biomarker gene set comprises HES1 and MYC, wherein the average expression level of said gene set above or below a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

79. The method according to claim 74, wherein the predictive biomarker gene set comprises HES1 and HES5, wherein the average expression level of said gene set above or below a pre-determined cut-off level is predictive of the patient'"'"'s treatment response to the anti-cancer agent.

80. The method according to any one of claim 74, wherein said patient is more likely than not to respond favorably to treatment with said Notch inhibitor when the expression levels of said biomarker gene in said clinical sample is increased relative to the cut-off level.

81. The method according to claim 80, wherein said patient is predicted to be sensitive to treatment with said Notch inhibitor.

82. The method according to any one of claim 74 wherein the pre-determined cut-off level has at least a statistically significant p-value over-expression in the biological sample comprising cancer cells relative to cells or tissue from normal patient or a patient not exhibiting aberrant Notch signaling.

83. The method according to any one of claim 74 wherein the pre-determined cut-off levels are at least 1 to 2 fold over-expressed in the biological sample relative to cells or tissue from a non-cancerous patient or cells or tissue comprising non-cancerous cells.

84. The method according to claim 83, wherein the p-value is less than 0.05.

85. The method according to claim 74 wherein gene expression is measured on a microarray or gene chip.

86. The method according to claim 85 wherein the microarray is a cDNA array or an oligonucleotide array.

87. The method according to claim 86 wherein the microarray or gene chip further comprises one or more internal control reagents.

88. The method to claim 74 wherein gene expression is determined by nucleic acid amplification conducted by polymerase chain reaction (PCR) of RNA extracted from the sample.

89. The method according to claim 74, wherein gene expression is detected by measuring or detecting a polypeptide encoded by the gene.

90. The method according to claim 89, wherein the polypeptide is detected by performing immunohistochemical analysis on the sample using an antibody that specifically binds to the polypeptide.

91. The method according to claim 74 wherein gene expression is detected by measuring a characteristic of the gene.

92. The method according to claim 74 wherein gene expression level is compared to an expression level of a control sample.

93. The method according to claim 74 wherein the determining step comprises detecting the RNA transcript levels.

94. The method according to claim 74, wherein said control is the average level of expression of each of said plurality of genes in a sample obtained from a disease free subject or a subject whose cells do not exhibit aberrant Notch signaling.

95. The method according to claim 74, wherein said average is the average level of expression of each of said plurality of genes across a plurality of control samples derived from disease free subjects.

96. A method for stratifying a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) for a clinical trial comprising:

(a) detecting a measured level of expression of a Notch biomarker gene set one in a clinical sample of diseased cells comprising cancer cells obtained from said subject with a control sample, and

(b) stratifying the patient for the clinical trial based on the results of the detecting step, wherein said gene set comprises HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA and SHQ1.

97. The method according to claim 96, wherein said gene set comprises DTX1.

98. The method according to claim 96, wherein said gene set comprises HES1 and HES5.

99. The method according to claim 96, wherein said gene set comprises HES1.

100. The method according to claim 96, wherein said gene set comprises HES5.

101. The method according to claim 96, wherein said gene set comprises HES1 and MYC.

102. A method for determining whether a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) is likely to respond to a Notch inhibitor based therapy comprising the steps of:

(a) quantifying the average expression level of a plurality of genes in a clinical sample of diseased cells obtained from a patient diagnosed with a Notch mediated cancer, wherein said plurality is genes is selected from the group comprising Group 1, Group 2 or Group 3, and

(b) comparing the average expression level obtained from the clinical sample to that obtained from a control sample, wherein an increase in the average expression in the clinical sample relative to the control sample indicates that the patient is more likely to respond to treatment with a Notch inhibitor;

wherein Group 1 comprises HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA and SHQ1HES1 and MYC;

Group 2 comprises HES and HES5;

Group 3 comprises HES1 and MYC.

103. The method according to claim 102, wherein said average level of expression in the clinical sample is the average level of expression of each of said plurality of genes.

104. The method according to claim 102, wherein said control is the average level of expression of each of said plurality of genes in a sample obtained from a disease free subject or a subject whose cells do not exhibit aberrant Notch signaling.

105. The method according to claim 102, wherein said average is the average level of expression of each of said plurality of genes across a plurality of control samples derived from disease free subjects.

106. A method of predicting the response of a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) to a Notch inhibitor, comprising:

determining in a biological sample comprising cancer cells obtained from a patient after administration of a therapeutically effective amount of said Notch inhibitor the gene expression level of at least one target gene selected from the group consisting of HES4, HES5, DTX1, MYC, and SHQ1;

wherein a change in the gene expression level of said at least one target gene relative to a control correlates with treatment response.

107. The method according to claim 106, wherein an increase in said mean average gene expression level of said at least one target gene in said biological sample obtained from said patient relative to a control sample correlates with poor prognosis of treatment response with said Notch inhibitor.

108. A method of predicting the response of a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) to a Notch inhibitor, comprising:

determining in a biological sample comprising cancer cells obtained from a patient after administration of a therapeutically effective amount of said Notch inhibitor the gene expression level of at least one target gene selected from the group consisting of HES4, MYC, and SHQ1;

wherein a change in the gene expression level of said at least one target gene relative to a control correlates with treatment response.

109. The method according to claim 108, wherein an increase in said mean average gene expression level of said at least one target gene in said biological sample obtained from said patient relative to a control sample correlates with poor prognosis of treatment response with said Notch inhibitor.

110. A method of predicting the response of a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) to a Notch inhibitor, comprising determining in a biological sample comprising cancer cells obtained from a patient after administration of a therapeutically effective amount of said Notch inhibitor the average gene expression level of a gene set comprising a plurality of genes selected from the group consisting of HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA and SHQ1 such as to obtain a mean average gene expression level, wherein a mean average gene expression level above or below a pre-determined cut-off level correlates with treatment response.

111. The method according to claim 110, wherein the determining step is carried out by a method comprising comparing the mean average level of gene expression of said plurality of genes in said set to the mean average gene expression level of the same genes in a control sample.

112. The method according to claim 110, wherein said control is the average level of expression of each of said plurality of genes in a sample of non-diseased cells or cells that do not exhibit aberrant Notch signaling or activation.

113. The method according to claim 110, wherein an increase in said mean average gene expression level of said plurality of genes in said gene set relative to a control sample correlates with poor prognosis of treatment response with said Notch inhibitor.

114. The method according to claim 110, wherein a decrease in said mean average gene expression level of said plurality of genes in said gene set relative to a control sample correlates with a good prognosis of treatment response with said Notch inhibitor.

115. A method of predicting the response of a patient diagnosed with a Notch mediated cellular proliferative disorder (T-ALL) to a Notch inhibitor, comprises determining in a biological sample comprising cancer cells obtained from a patient after administration of a therapeutically effective amount of said Notch inhibitor the gene expression level of at least one target gene selected from the group consisting of p19, p21 and p27, wherein a change in gene expression level of said at least one target gene above or below a pre-determined cut-off level correlates with treatment response.

116. The method according to claim 115, wherein the determining step is carried out by a method comprising comparing the gene expression of level of at least one of said target gene to the corresponding gene expression level in a control sample.

117. The method according to claim 115, wherein said control is the gene expression level determined in a control sample of non-diseased cells, or cells that do not exhibit aberrant Notch signaling or activation.

118. The method according to claim 115, wherein an increase in gene expression level of said at least one target gene in said biological sample obtained from said patient relative to a control sample correlates with good prognosis of treatment response with said Notch inhibitor.

119. A method to determine whether a patient diagnosed with a Notch mediated cancer (T-ALL) should continue treatment with a Notch inhibitor, comprising the steps of:

(a) determining the level of expression of at least one gene selected from the group consisting of p19, p21 and p27 in a clinical sample of cancer cells obtained from said patient prior to administering a therapeutically effective amount of a Notch inhibitor to said patient to obtain a pre-dosing level and after administration of said Notch inhibitor to obtain a post-dose level, and

(b) comparing said pre-dose and post-dose levels in said sample, wherein an increase in the expression level at least one biomarker gene selected from the group consisting of p19, p21 and p27 post-dose is predictive of said patient having a favorable response to treatment with said Notch inhibitor, whereas a decrease in the expression pattern of said at least one biomarker gene post-dose is predictive of an unfavorable response to treatment with said Notch inhibitor.

120. A method to determine whether a patient diagnosed with a Notch mediated cancer (T-ALL) should continue treatment with a Notch inhibitor, comprising determining the level of expression of at least one gene selected from the group consisting of HES4, HES5, DTX1, MYC and SHQ1 in a clinical sample of cancer cells obtained from said patient prior to administering a therapeutically effective amount of a Notch inhibitor to said patient to obtain a pre-dosing level and after administration of said Notch inhibitor to obtain a post-dose level, wherein a decrease in the expression level of said at least one biomarker gene post-dose is predictive of said patient having a favorable response to treatment with said Notch inhibitor.

121. A method to determine whether a patient diagnosed with a Notch mediated cancer (T-ALL) should continue treatment with a Notch inhibitor, comprising the steps of:

(a) determining the average level of expression of each of a plurality of biomarker gene selected from the group consisting of HES1, HES4, HES5, HESL, HEY-2, MYC, NRARP, PTCRA, DTX1 in a clinical sample of cancer cells obtained from said patient aid prior to (pre-dose) and after (post-dose) administration of a therapeutically effective amount of a Notch inhibitor to said patient to obtain a pre-dosing level, and

(b) quantifying said level of expression in each of the pre- and post-dose samples to obtain an average mean level of expression, wherein a decrease in the average level of expression in the post-dose sample relative to the pre-dose sample is predictive of said patient having a favorable response to treatment with said Notch inhibitor, whereas an increase in the average mean expression level in said post-dose sample relative to the pre-dose sample is predictive of an unfavorable response to treatment with said Notch inhibitor.

122. A method for determining the therapeutic efficacy of a Notch inhibitor for treating a Notch mediated cellular proliferative disorder (T-ALL) comprising assaying a sample of diseased cells from said subject to determine and quantify a mean average expression level of each of a plurality of genes selected from the group consisting of HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA, SHQ1 at a first time point after administration of a therapeutically effective amount of said Notch inhibitor, wherein a decrease in the mean average level of expression of said plurality if genes relative to a control sample is indicative of the therapeutic efficacy of said Notch inhibitor.

123. The method according to claim 122, further comprising the step of assaying a sample of diseased cells post administration over at least one additional time point, wherein a decrease in the mean average expression level is indicative of the therapeutic efficacy of said inhibitor.

124. A method for determining the therapeutic efficacy of a Notch inhibitor for treating a Notch mediated cellular proliferative disorder (T-ALL) comprising the step of assaying a sample of diseased cells for expression levels of at least one biomarker gene selected from the group consisting of p19, p21 and p27 post administration of said Notch inhibitor over a period of time, wherein an increase in the level of expression of said at least one biomarker gene over a period of time relative to a control sample is indicative of the therapeutic efficacy of said Notch inhibitor.

125. A method of determining a therapeutically effective dosage of a Notch inhibitor to effectively treat a Notch mediated cellular proliferative disorder (T-ALL) in a subject comprising the steps of:

(a) administering to a diseased non-human animal varying dosages of said Notch inhibitor,

(b) determining in a biological sample obtained from said subject after administration of each dosage a gene expression profile of at least one biomarker gene selected from the group consisting of HES1, HES4, HES5, HESL, HEY-2, DTX1, MYC, NRARP, PTCRA, SHQ1, p19, p21, and p27; and

(c) selecting an appropriate dosage based upon the results of the gene expression profile.

126. The method according to claim 125, wherein determining gene expression profiles comprises determining the gene expression level of at least one said biomarker gene across a plurality of biological samples relative to a control or a pre-determined cut-off level.

127. The method according to claim 125, wherein the appropriate dosage correlates with gene expression levels above or below a pre-determined cut-off level.

128. The method according to claim 125, wherein the step of selecting the appropriate dosage comprises selecting a dosage regiment that results in a statistically significant decrease or increase in the gene expression level of said at least one gene relative to a control.